Spiro Medical, Inc., an Irvine, California-based clinical-stage medical device company, announced on October 12, 2026, that it had treated the first patient in its PULSAR feasibility study, an FDA-authorised clinical investigation evaluating implantable pulmonary neuromodulation for patients with uncontrolled asthma. The patient underwent implantation at The Orthopedic Institute in Gainesville, Florida, through a study site associated with the University of Florida’s Lillian S. Wells Department of Neurosurgery. The prospective, randomised investigation plans to enrol up to 30 patients across multiple United States centres, examining whether targeted spinal nerve stimulation can improve asthma control in patients who remain symptomatic despite established medicines.
The development marks a transition from earlier research into a controlled clinical evaluation of Spiro Medical’s purpose-built Pulmonary Neuromodulation System. Unlike inhaled corticosteroids, bronchodilators and injectable biologics, the investigational technology uses electrical stimulation delivered through an implanted spinal cord stimulation system to influence neural pathways associated with respiratory function. The company’s therapeutic hypothesis is that modifying nerve activity could help address aspects of airway hyperresponsiveness that remain inadequately controlled by pharmacological treatment.
However, the first-patient milestone does not establish that the device improves lung function, prevents asthma attacks or reduces reliance on medication. Spiro Medical has not disclosed efficacy or safety outcomes from the newly initiated PULSAR investigation, and the technology remains investigational rather than approved for commercial use. Its next challenge is to demonstrate that the proposed neurological intervention produces measurable clinical benefits that justify implantation and ongoing device management.
How is Spiro Medical’s PULSAR trial testing spinal nerve stimulation for uncontrolled asthma?
PULSAR, formally titled Pulmonary Stimulation for Asthma Relief, is registered as NCT07709754 and uses a prospective, multicentre, randomised, controlled feasibility design. The study plans to recruit approximately 30 adults aged 18 to 75 years across three to five United States sites, with participants followed for six months. The trial is intended to generate preliminary evidence about device safety and treatment effectiveness rather than serve as a definitive pivotal study supporting immediate commercial approval.
The study design contains an important control feature. Participants are randomised between immediate activation and delayed activation of the implanted neurostimulation system. Both groups undergo implantation at the beginning of the study, but stimulation begins immediately in the active-treatment group and after approximately 90 days in the delayed-activation group.
This approach allows investigators to compare early outcomes between patients receiving active electrical stimulation and those who have undergone implantation but have not yet received the intended stimulation therapy. The registered protocol also describes masking of participants, care providers and investigators. Such controls are particularly relevant when evaluating outcomes involving symptoms and quality of life, which can be influenced by patient expectations and the experience of undergoing a medical procedure.
The trial’s registered primary endpoint measures the proportion of participants achieving an Asthma Control Test score above 19 at three months. A score in this range generally indicates well-controlled asthma, making the endpoint relevant to the proposed treatment objective. The study also includes a secondary assessment of clinically meaningful improvement in asthma-related quality of life.
Although the trial has a relatively small sample size, its delayed-activation design can provide useful early evidence about whether stimulation produces a signal beyond implantation and associated expectations. Nevertheless, even favourable results would need to be interpreted in the context of the study’s limited statistical power and follow-up duration. Larger investigations would likely be necessary to establish efficacy, uncommon adverse-event risks and longer-term durability.
Who qualifies for the investigational asthma implant, and why is patient selection important?
Spiro Medical’s announcement emphasises patients with severe asthma whose symptoms remain uncontrolled despite optimised pharmacological treatment, including biologic medicines. The registered protocol describes a population with moderate to severe uncontrolled asthma diagnosed by an allergist or pulmonologist for at least one year. Participants must demonstrate inadequate symptom control despite high-dose inhaled corticosteroid and long-acting beta-agonist treatment and/or biologic therapy, together with an Asthma Control Test score of 15 or below.
The study also incorporates previous or current biologic treatment within its eligibility criteria. This is relevant because biologic medicines have substantially expanded the options available for selected patients with severe asthma, particularly those with inflammatory characteristics that respond to targeted treatment. Patients continuing to experience significant symptoms despite these treatments represent an important clinical population for investigating additional approaches.
However, the study does not enrol every patient with difficult-to-control asthma. Its exclusion criteria address several medical conditions that could influence procedural safety or complicate interpretation of treatment outcomes, including certain cardiovascular disorders, chronic pulmonary diseases other than asthma, neurological conditions and previous thoracic spinal surgery. Existing implanted electronic devices and factors affecting surgical suitability can also restrict participation.
These exclusions are important because spinal cord stimulation requires an invasive intervention rather than administration of a medicine. Patients must be appropriate candidates for implantation, and the procedure introduces considerations that do not apply to conventional inhaled treatment. Consequently, any future positive results would initially be most applicable to patients resembling those actually enrolled, rather than the entire population with severe asthma.
How does pulmonary neuromodulation aim to influence airway function without introducing another asthma drug?
Asthma is characterised by chronic airway inflammation, variable airflow limitation and heightened sensitivity of the airways to different triggers. Conventional treatment strategies primarily focus on reducing inflammation, relaxing airway smooth muscle and preventing exacerbations. Spiro Medical is investigating a complementary mechanism involving the autonomic nervous system and its contribution to respiratory regulation.
Autonomic nerve pathways influence airway smooth muscle tone, mucus production and other physiological functions associated with breathing. Neural reflexes can also contribute to responses triggered by irritants and other stimuli. The company believes targeted stimulation at the thoracic spinal level may modify these pathways in ways that reduce asthma-related symptoms.
Its investigational system delivers electrical stimulation through implanted hardware positioned to influence relevant spinal neural activity. The objective is not to remove airway tissue or deliver a pharmaceutical compound directly into the lungs. Instead, the approach seeks to change neural signalling associated with respiratory function.
The distinction is scientifically interesting because asthma involves interactions between immune activity, airway structure and neurological regulation. Nevertheless, the existence of neural pathways influencing bronchial function does not establish that stimulating them will produce clinically meaningful asthma control. The appropriate stimulation parameters, consistency of response and potential effects on inflammatory activity remain questions requiring direct clinical evidence.
Spiro Medical describes its platform as a complementary treatment for patients whose disease remains uncontrolled despite medication. This positioning is important because the PULSAR study has not established that pulmonary neuromodulation can replace inhaled corticosteroids, biologics or other evidence-based treatments. Any eventual role would depend on demonstrated benefit, safety and the approved conditions of use.
Why are the Asthma Control Test and quality-of-life endpoints central to the PULSAR study?
The Asthma Control Test is a validated patient-reported instrument used to assess symptoms and the effect of asthma on daily activities over a defined period. Scores range from 5 to 25, with higher scores indicating better control. PULSAR’s primary endpoint focuses on the proportion of participants achieving a score above 19 after three months, allowing investigators to evaluate whether the intervention is associated with movement into a better-controlled clinical category.
This is a relevant early outcome because patients with uncontrolled asthma may experience persistent breathlessness, sleep disruption and limitations in physical activity even while receiving substantial pharmacological treatment. Improvement in symptom control could therefore represent a meaningful benefit for individuals whose existing treatment has not achieved adequate relief. However, patient-reported symptom improvement does not automatically demonstrate reduced airway inflammation or protection against severe future exacerbations.
The secondary outcome uses the Asthma Quality of Life Questionnaire to evaluate whether changes in symptoms are reflected in everyday functioning and well-being. This assessment can capture aspects of disease burden that may not be fully represented by conventional physiological measurements. The registered study measures the proportion of patients achieving a clinically meaningful improvement rather than relying exclusively on average score changes.
The six-month observation period should provide information about whether any initial response persists after device activation. It also creates an opportunity to examine outcomes among participants whose stimulation begins later in the study. However, longer follow-up would be necessary to determine whether benefits can be maintained over years, whether stimulation settings require adjustment and how device-related complications evolve with continued implantation.
An important additional question will be whether changes in asthma control correspond with objective respiratory measurements. Improvements in lung function, exacerbation frequency or corticosteroid exposure would add context to symptom-based endpoints if appropriately measured and reported. The publicly registered primary endpoint alone does not establish that the study is powered to detect differences in severe asthma attacks or hospitalisations.
What procedural and device safety risks must Spiro Medical evaluate during the feasibility study?
Implantable spinal cord stimulation introduces a different safety profile from medicines administered by inhalation or injection. Potential risks associated with the general category of implanted neurostimulation systems include infection, discomfort at the implantation site, lead displacement, device malfunction and complications involving neural structures. The frequency and severity of these events with Spiro Medical’s particular system have not yet been established through the PULSAR study.
Device safety also extends beyond the implantation procedure itself. Investigators must assess whether electrical stimulation is tolerated during routine activity and whether it produces unintended physiological effects. Because the technology is designed to influence respiratory-related neural pathways, treatment assessment should consider any unexpected changes in breathing, discomfort or other clinically relevant responses.
The registered study includes exclusion criteria addressing implanted devices, relevant neurological disorders and certain cardiovascular conditions. These restrictions help define a population in which early evaluation can take place under controlled conditions. They also highlight the potential challenges of extending the technology to a broader patient population with multiple chronic medical conditions.
Another important consideration is the balance between invasiveness and expected clinical benefit. Some patients with severe asthma already receive effective treatment through biologic injections administered at scheduled intervals, while others remain inadequately controlled despite extensive therapy. An implanted device would need to offer sufficient additional benefit to justify the procedural requirements, follow-up visits and possible future device interventions.
The October 12 announcement confirmed that the first participant had undergone implantation but did not provide detailed information about procedural complications or post-implant recovery. It would therefore be premature to conclude that implantation has been demonstrated to be safe in this population. Those questions are among the reasons a structured feasibility investigation is necessary before larger-scale clinical development.
How does spinal cord stimulation compare with established severe asthma treatment and bronchial thermoplasty?
The treatment environment for severe asthma has changed considerably with the introduction of biologic medicines targeting inflammatory pathways. Depending on patient characteristics and approved indications, clinicians may use therapies directed at immunoglobulin E, interleukin-5, interleukin-4 receptor signalling or thymic stromal lymphopoietin. These medicines have established clinical evidence in defined populations, although treatment responses vary and some patients continue experiencing substantial disease burden.
Bronchial thermoplasty provides another relevant comparison because it is a device-based intervention rather than a conventional medicine. The procedure delivers controlled radiofrequency energy to the airway wall through bronchoscopy, with the aim of reducing airway smooth muscle. Its role remains relatively restricted, reflecting considerations involving patient selection, procedural burden and uncertainty about longer-term benefits compared with contemporary treatment options.
Spiro Medical’s proposed approach differs from bronchial thermoplasty because it targets neural regulation rather than directly treating airway tissue. It is also intended to provide ongoing stimulation through implanted hardware rather than relying on a defined series of bronchoscopic interventions. These differences create distinct questions involving device programming, reversibility, procedural risks and durability.
There is no evidence from a head-to-head trial demonstrating that Spiro Medical’s investigational therapy is more effective than biologics, bronchial thermoplasty or another established asthma treatment. Its clinical positioning remains exploratory, and outcomes from different treatment trials cannot be reliably compared without accounting for patient selection and study methodology. The appropriate benchmark will ultimately be whether neuromodulation provides meaningful additional benefit for the patients it is intended to serve.
What does FDA Investigational Device Exemption approval mean for Spiro Medical’s regulatory pathway?
The PULSAR study is being conducted under an Investigational Device Exemption approved by the United States Food and Drug Administration. This authorisation allows the investigational device to be evaluated in a clinical study under the applicable regulatory and ethical requirements. It is not a marketing approval, a 510(k) clearance or confirmation that the device is effective for treating asthma.
The study is a feasibility investigation designed to support early assessment of the technology and inform subsequent development. Results may help Spiro Medical determine whether the device design, stimulation strategy and clinical endpoints are suitable for larger investigations. They may also identify changes needed to improve the procedure or refine patient selection.
The company has not announced a completed pivotal trial, submitted marketing application or expected FDA approval date. Any future United States commercialisation would depend on the applicable regulatory pathway and the evidence necessary to establish safety and effectiveness for the proposed indication. Spiro Medical’s October announcement therefore represents clinical development progress rather than regulatory validation of a new asthma treatment.
According to the study registration, primary completion was estimated for January 2027, with overall study completion estimated for June 2027. These dates are planning estimates rather than confirmed result-announcement deadlines. Recruitment, follow-up requirements and study amendments could influence the eventual timing of the first complete dataset.
How will Spiro Medical’s $67 million financing support further asthma device development?
Spiro Medical entered 2026 with financial backing intended to support the development of its pulmonary neuromodulation platform. In January, the company announced a $67 million Series A equity financing involving investors led by Andera Partners, Omega Funds and Sherpa Healthcare Partners. Additional participants included HSG, Supernova Invest, Northern Light Venture Capital and Hero Inc., part of Hero Enterprise.
The financing was intended to advance the company’s purpose-built neuromodulation system and support clinical activities required for United States regulatory development. Initiation of the FDA-authorised PULSAR study represents a tangible step in that strategy. However, the company has not disclosed an updated cash balance, operating expenditure profile or specific allocation of capital to the feasibility programme.
Spiro Medical remains privately held and has no publicly traded share price through which investors can assess the immediate market reaction to the first-patient announcement. Its valuation and commercial revenue expectations were not disclosed in the October release. The clinical milestone therefore provides evidence of development execution rather than an established commercial revenue opportunity.
A future commercial model would involve considerations beyond the performance of the implanted neurostimulator. Hospitals would need to assess implantation requirements, specialist training, device programming, follow-up services and potential revision procedures. Reimbursement would also need to address both the implant and associated medical services under whatever regulatory indication might eventually be authorised.
The potential addressable population cannot be inferred directly from overall asthma prevalence. Only a subset of patients have severe or persistently uncontrolled disease, and fewer may satisfy the clinical and surgical requirements for an implanted device. Meaningful commercial forecasts will require a more precise understanding of eligible patients, treatment outcomes, costs and clinical adoption.
What will determine whether PULSAR advances from feasibility testing to a larger asthma trial?
The immediate milestone will be completion of enrolment and follow-up in the planned 30-patient investigation. Investigators will assess whether active stimulation produces a meaningful improvement in the proportion of participants achieving controlled asthma at three months, compared with the delayed-activation group. The quality-of-life results will provide additional evidence about whether the intervention changes the patient’s everyday experience of the disease.
Safety findings will carry substantial weight because this is an invasive treatment proposed for a condition commonly managed with medicines. Researchers will need to establish whether device implantation and continued stimulation are sufficiently well tolerated to justify broader evaluation. Any complications associated with surgery, implanted hardware or electrical stimulation could influence the design of a subsequent study.
The trial may also help clarify whether changes in stimulation settings or patient selection could improve treatment consistency. Severe asthma is biologically heterogeneous, and different patients may respond differently depending on their underlying inflammatory and neurological characteristics. A small feasibility study can generate hypotheses about these differences, but it cannot reliably establish which subgroups will benefit most.
Spiro Medical’s first-patient treatment marks a meaningful operational step in the development of pulmonary neuromodulation for uncontrolled asthma. The PULSAR study introduces a controlled comparison of immediate and delayed spinal nerve stimulation, providing a more rigorous framework for investigating the company’s proposed mechanism than uncontrolled observations alone. Its clinical significance will ultimately depend on whether the implanted system can demonstrate sustained improvement in asthma control and quality of life, with procedural and device-related risks acceptable for patients who remain symptomatic despite established treatment.
